Retraction Note: Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1α levels contribute to emergence of an aggressive phenotype in prostate cancer (Oncogene, 10.1038/onc.2008.476);Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1α levels contribute to emergence of an aggressive phenotype in prostate cancer

Oncogene

Volumn 28, Issue 9, 2009, Pages 1248-1260

  Khandrika, L ^a   Lieberman, R ^a   Koul, S ^a   Kumar, B ^a   Maroni, P ^a,b   Chandhoke, R ^a   Meacham, R B ^a,b   Koul, H K ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Androgen independence; HIF 1 ; p38 MAPK; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE P38;

ARTICLE; CANCER CELL; CELL CLONING; CELL INVASION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REOXYGENATION;

EID: 62049086265     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-022-02357-z     Document Type: Erratum

References (42)

1. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J et al. (2001). Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554.
2. Asirvatham AJ, Schmidt M, Gao B, Chaudhary J. (2006). Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinology 147: 257-271.
3. Baek SH, Lee UY, Park EM, Han MY, Lee YS, Park YM. (2001). Role of protein kinase C delta in transmitting hypoxia signal to HSF and HIF-1. J Cell Physiol 188: 223-235.
4. Berra E, Pagès G, Pouysségur J. (2000). MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19: 139-145.
5. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, Livingston DM. (1999). Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 13: 64-75.
6. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S et al. (2005). The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11: 7658-7663.
7. Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR et al. (2008). Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer 123: 760-768.
8. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G. (2008). Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 68: 285-291.
9. Carmeliet P, Jain RK. (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
10. Cheng WS, Giandomenico V, Pastan I, Essand M. (2003). Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter. Endocrinology 144: 3433-3440.
11. Culig Z, Bartsch G. (2006). Androgen axis in prostate cancer. J Cell Biochem 99: 373-381.
12. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y et al. (2007). Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 5: 383-391.
13. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. (1983). LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818.
14. Huggins C, Hodges CV. (1941). Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297.
15. Kimbro KS, Simons JW. (2006). Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13: 739-749.
16. Kokontis JM, Hay N, Liao S. (1998). Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953.
17. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. (2008). Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68: 1777-1785.
18. Kwon SJ, Song JJ, Lee YJ. (2005). Signal pathway of hypoxia-inducible factor-1alpha phosphorylation and its interaction with von Hippel-Lindau tumor suppressor protein during ischemia in MiaPaCa-2 pancreatic cancer cells. Clin Cancer Res 11: 7607-7613.
19. Luo Y, He DL, Ning L, Shen SL, Li L, Li X et al. (2006). Overexpression of hypoxia-inducible factor-1alpha increases the invasive potency of LNCaP cells in vitro. BJU Int 98: 1315-1319.
20. Maroni PD, Koul S, Chandhoke PS, Meacham RB, Koul HK. (2005). Oxalate toxicity in cultured mouse inner medullary collecting duct cells. J Urol 174: 757-760.
21. McDonald DM, Choyke PL. (2003). Imaging of angiogenesis: from microscope to clinic. Nat Med 9: 713-725.
22. Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T et al. (2007). Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 67: 6022-6025.
23. Miyazaki Y, Hara A, Kato K, Oyama T, Yamada Y, Mori H et al. (2008). The effect of hypoxic microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell carcinoma. Int J Oncol 32: 145-151.
24. Mortimer HJ, Peacock AJ, Kirk A, Welsh DJ. (2007). p38 MAP kinase: essential role in hypoxia-mediated human pulmonary artery fibroblast proliferation. Pulm Pharmacol Ther 20: 718-725.
25. Murata M, Yudoh K, Nakamura H, Kato T, Inoue K, Chiba J et al. (2006). Distinct signaling pathways are involved in hypoxia- and IL-1-induced VEGF expression in human articular chondrocytes. J Orthop Res 24: 1544-1554.
26. Pagès G, Berra E, Milanini J, Levy AP, Pouysségur J. (2000). Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 275: 26484-26491.
27. Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, Hidalgo AA et al. (2006). Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 66: 5121-5129.
28. Pouysségur J, Dayan F, Mazure NM. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
29. Powell CS, Wright MM, Jackson RM. (2004). p38mapk and MEK1/2 inhibition contribute to cellular oxidant injury after hypoxia. Am J Physiol Lung Cell Mol Physiol 286: L826-L833.
30. Repesh LA. (1989). A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 9: 192-208.
31. Rizzino A. (1987). Soft agar growth assays for transforming growth factors and mitogenic peptides. Methods Enzymol 146: 341-352.
32. Shida Y, Igawa T, Hakariya T, Sakai H, Kanetake H. (2007). p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion. Biochem Biophys Res Commun 353: 744-749.
33. Sumbayev VV, Yasinska IM. (2005). Regulation of MAP kinase-dependent apoptotic pathway: implication of reactive oxygen and nitrogen species. Arch Biochem Biophys 436: 406-412.
34. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R et al. (2006). Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res 66: 9519-9526.
35. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y et al. (2005). Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58: 172-177.
36. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB et al. (1999). The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 18: 4969-4980.
37. Xu L, Chen S, Bergan RC. (2006). MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 25: 2987-2998.
38. Yoshino Y, Aoyagi M, Tamaki M, Duan L, Morimoto T, Ohno K. (2006). Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. Int J Oncol 29: 981-987.
39. Zetter BR. (1998). Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424.
40. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB et al. (1998). Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res 58: 5280-5284.
41. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM et al. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545.
42. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P et al. (2007). Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67: 10455-10465.